Kjaer M, Bendixen G
Ann N Y Acad Sci. 1976;276:260-71. doi: 10.1111/j.1749-6632.1976.tb41652.x.
Leucocyte migration inhibition detected in vitro by the capillary tube technique (LMCT) has proved a useful tool for detection of tumor-specific cell-mediated hypersensitivity (TCMH) in man. Investigations in pateints with renal tumors are reported. It is shown that TCMH is a feature of hypernephroma in man, that the antigenic specificity is found in autologous as well as allogeneic tumor tissue and in fetal kidney tissue. The pattern of reactivity compared to postoperative survival and occurrence of metastases and postoperative clinical course shows a clear association between TCMH and tumor elimination. The capacity of hypernephroma patients to develop a cell-mediated immune response is generally not reduced. In allogeneic combinations, small noninvading tumors usually have a high antigenicity, whereas tumors with early dispersion show a low antigenicity. The development of TCMH and associated tumor elimination therefore may be depending preferably on the antigenicity of the tumor, less on the immune capacity of the tumor host.
通过毛细管技术(LMCT)在体外检测到的白细胞迁移抑制已被证明是检测人类肿瘤特异性细胞介导超敏反应(TCMH)的一种有用工具。本文报道了对肾肿瘤患者的研究。结果表明,TCMH是人类肾上腺样瘤的一个特征,其抗原特异性存在于自体以及同种异体肿瘤组织和胎儿肾组织中。与术后生存率、转移发生率和术后临床病程相比,反应模式显示TCMH与肿瘤清除之间存在明显关联。肾上腺样瘤患者产生细胞介导免疫反应的能力通常并未降低。在同种异体组合中,小的无侵袭性肿瘤通常具有高抗原性,而早期扩散的肿瘤则显示低抗原性。因此,TCMH的发展和相关的肿瘤清除可能主要取决于肿瘤的抗原性,而较少取决于肿瘤宿主的免疫能力。